We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+46.67%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$235M
Cap. Flow
-$27.9M
Cap. Flow %
-2.69%
Top 10 Hldgs %
62.46%
Holding
79
New
20
Increased
8
Reduced
18
Closed
12

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$12.9M
2
NVO
Novo Nordisk
NVO
+$12.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.92M
4
HALO icon
Halozyme
HALO
+$6.5M
5
BPMC
Blueprint Medicines
BPMC
+$5.31M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$43.8M
2
SNY icon
Sanofi
SNY
+$14.2M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.3M
5
INCY icon
Incyte
INCY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 83.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$118M 11.33%
998,538
-500,000
-33% -$43.8M
AMRN
2
Amarin Corp
AMRN
$284M
$108M 10.42%
260,415
– –
PRNB
3
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$69.3M 6.68%
2,038,208
– –
NTRA icon
4
Natera
NTRA
$37.5B
$63.9M 6.16%
3,100,560
– –
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$60.7M 5.86%
4,749,623
– –
YMAB
6
DELISTED
Y-mAbs Therapeutics
YMAB
$55.2M 5.32%
2,104,278
– –
ONCE
7
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$54.8M 5.28%
481,270
– –
CHRS icon
8
Coherus Oncology
CHRS
$217M
$39.1M 3.77%
2,868,221
– –
NCNA
9
NuCana
NCNA
$5.37M
$38.5M 3.71%
453
– –
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
$36.4M 3.51%
933,640
– –
MRUS
11
DELISTED
Merus
MRUS
$29M 2.79%
1,961,039
– –
OEF icon
12
PUT
iShares S&P 100 ETF
OEF
$19.8B
$27.1M 2.61%
+242,000
New +$29.1M
KNSA icon
13
Kiniksa Pharmaceuticals
KNSA
$4.83B
$16.7M 1.61%
922,700
– –
ITRM
14
DELISTED
Iterum Therapeutics
ITRM
$13.7M 1.32%
115,101
– –
AGN
15
DELISTED
Allergan plc
AGN
$13M 1.25%
+88,665
New +$12.9M
NVO
16
Novo Nordisk
NVO
$216B
$13M 1.25%
+495,468
New +$12.2M
ABBV icon
17
CALL
AbbVie
ABBV
$458B
$12.1M 1.17%
+150,000
New +$12.3M
ACRS icon
18
Aclaris Therapeutics
ACRS
$730M
$11.4M 1.1%
1,911,573
– –
AZN icon
19
AstraZeneca
AZN
$263B
$10.6M 1.02%
130,789
-27,375
-17% -$2.16M
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$36.3B
$9.96M 0.96%
+106,616
New +$8.92M
NBIX icon
21
Neurocrine Biosciences
NBIX
$17.7B
$9.9M 0.95%
112,406
+50,906
+83% +$4.25M
BIIB icon
22
CALL
Biogen
BIIB
$29.9B
$9.46M 0.91%
+40,000
New +$12.6M
MGNX icon
23
MacroGenics
MGNX
$235M
$9.42M 0.91%
523,756
+190,835
+57% +$3.3M
CHMA
24
DELISTED
Chiasma, Inc. Common Stock
CHMA
$8.48M 0.82%
1,630,221
– –
ETTX
25
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$7.97M 0.77%
1,180,178
– –
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2019 Portfolio in Review

As of Q1 2019, Sofinnova Investments held 79 positions worth $1.04B, up 29% from $803M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sofinnova Investments's Q1 2019 filing shows 20 new, 8 increased, 18 reduced and 12 closed positions. Its largest new stake was Allergan plc: 88,665 shares worth $13M. The largest sale was Ascendis Pharma A/S, an estimated $43.8M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 91% a quarter earlier.

  • Sofinnova Investments's largest Q1 2019 buy was Allergan plc: 88,665 shares worth $13M.
  • Sofinnova Investments added most to AnaptysBio in Q1 2019, an estimated $5.03M increase.
  • Sofinnova Investments's biggest Q1 2019 reduction was Ascendis Pharma A/S, cutting an estimated $43.8M.
  • Sofinnova Investments fully exited Sanofi in Q1 2019, selling an estimated $14.2M.
  • Sofinnova Investments's ten largest holdings make up 62% of its $1.04B portfolio in Q1 2019.
  • Sofinnova Investments opened 20 new positions and closed 12 in Q1 2019.
  • Sofinnova Investments's portfolio value rose 29% quarter-over-quarter to $1.04B.

Based on Sofinnova Investments's 13F filing for Q1 2019, filed 15 May 2019.